Literature DB >> 34873002

Economic evaluation of an Australian nurse home visiting programme: a randomised trial at 3 years.

Shalika Bohingamu Mudiyanselage1, Anna M H Price2,3,4, Fiona K Mensah2,4, Hannah E Bryson2,3, Susan Perlen2,3, Francesca Orsini5,6, Harriet Hiscock3, Penelope Dakin7, Diana Harris7, Kristy Noble7, Tracey Bruce8, Lynn Kemp8, Sharon Goldfeld2,3,4, Lisa Gold9.   

Abstract

OBJECTIVES: To investigate the additional programme cost and cost-effectiveness of 'right@home' Nurse Home Visiting (NHV) programme in relation to improving maternal and child outcomes at child age 3 years compared with usual care.
DESIGN: A cost-utility analysis from a government-as-payer perspective alongside a randomised trial of NHV over 3-year period. Costs and quality-adjusted life-years (QALYs) were discounted at 5%. Analysis used an intention-to-treat approach with multiple imputation.
SETTING: The right@home was implemented from 2013 in Victoria and Tasmania states of Australia, as a primary care service for pregnant women, delivered until child age 2 years. PARTICIPANTS: 722 pregnant Australian women experiencing adversity received NHV (n=363) or usual care (clinic visits) (n=359). PRIMARY AND SECONDARY OUTCOME MEASURES: First, a cost-consequences analysis to compare the additional costs of NHV over usual care, accounting for any reduced costs of service use, and impacts on all maternal and child outcomes assessed at 3 years. Second, cost-utility analysis from a government-as-payer perspective compared additional costs to maternal QALYs to express cost-effectiveness in terms of additional cost per additional QALY gained.
RESULTS: When compared with usual care at child age 3 years, the right@home intervention cost $A7685 extra per woman (95% CI $A7006 to $A8364) and generated 0.01 more QALYs (95% CI -0.01 to 0.02). The probability of right@home being cost-effective by child age 3 years is less than 20%, at a willingness-to-pay threshold of $A50 000 per QALY.
CONCLUSIONS: Benefits of NHV to parenting at 2 years and maternal health and well-being at 3 years translate into marginal maternal QALY gains. Like previous cost-effectiveness results for NHV programmes, right@home is not cost-effective at 3 years. Given the relatively high up-front costs of NHV, long-term follow-up is needed to assess the accrual of health and economic benefits over time. TRIAL REGISTRATION NUMBER: ISRCTN89962120. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  community child health; health economics; primary care; public health

Mesh:

Year:  2021        PMID: 34873002      PMCID: PMC8650480          DOI: 10.1136/bmjopen-2021-052156

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


A randomised controlled trial setting, with regular follow-up and good retention over time for this disadvantaged population. Integration of a multiattribute utility instrument and detailed resource use items into trial data collection enables comprehensive assessment of costs and quality-adjusted life-year impact. Longer-term follow-up will be required to assess whether emerging benefits over time, as seen in similar programmes in the USA, recoup the large upfront cost.

Introduction

Nurse Home Visiting (NHV) programmes have been implemented in many high-income countries to improve the health and quality of life of mothers and their children.1 As one of the few early interventions that have been shown to effectively reduce inequitable outcomes for families experiencing socioeconomic and psychosocial adversity, they have substantial policy appeal.2 3 Previous NHV programmes have varied in their theory, content and targeted population.4–8 Most experimental evidence comes from the USA.9 In particular, the Nurse Family Partnership (NFP) has shown improvement in the parental care and material life course of high risk women in the USA,10 although similar benefits have been variable when translating this programme to other countries.4–8 NHV programmes are expensive, mostly due to providing additional professional services in-home at the family/individual level.10 In this context opportunities to implement these programmes are challenging with policy-makers requiring rigorous evidence of effectiveness and cost-effectiveness.11 Economic evaluations of NHV programmes are important to highlight how initial programme implementation costs weigh up against benefits and potential reduced service costs over time. Economic evaluations of NFP have found high upfront programme costs (US$12 265 per family in 2018 US$)12 with benefits that accrue to participants and taxpayers over the child’s lifetime, to produce positive returns on investment by child age 30 years.12 13 However, the evidence for cost-effectiveness of NHV programmes in countries with universal healthcare remains unclear or limited. From 2013, we trialled an NHV programme (right@home) for pregnant women experiencing psychosocial and socioeconomic adversity in Australia.14 The programme was embedded into the universal child and family health (CFH) service, which also provided the comparator. The Australian universal CFH service provides nurse visits at key stages of child’s health, learning and development. For example, in Victoria families receive CFH nurse visits following the hospital discharge (home visit) and, at 2 weeks, 4 weeks, 8 weeks, 4 months, 8 months, 1 year, 18 months, 2 years and 3.5 years at a local CFH clinic.15 By the time the right@home NHV programme was completed at child age 2 years, it had led to improved parenting and home environment outcomes over and above the usual service.14 Consistent with the NHV literature, it is anticipated that these short-term benefits will generate longer-term benefits to maternal and child health and development, potentially with associated reductions in government services.12 13 The aim of this economic evaluation is to analyse the cost-effectiveness of the right@home programme to improve maternal and child outcomes 1 year after programme delivery ended. Given the short (12-month) follow-up in the context of the NHV evidence base,10 12 13 we did not expect the right@home programme to be cost-effective by child age 3 years. Rather, we aimed to assess whether upfront programme costs were offset by any early maternal and child outcomes, as an indication that the NHV programme could achieve longer-term positive returns like those seen in the USA.

Methods

Design and analytic overview

The study design is an economic evaluation alongside a randomised controlled trial (RCT) of NHV compared with the usual CFH service. The evaluation considered pregnancy to child age 3 years and comprised two steps. First, a cost–consequences analysis from a government-as-payer perspective compared the additional costs of NHV over usual care, accounting for any reduced costs of service use, and impacts on the maternal and child outcomes assessed at 3 years. This multicriteria economic evaluation format incorporates all outcomes judged important in the trial, but results cannot be clearly interpreted as cost-effective or not.16 Second, cost–utility analysis from a government-as-payer perspective compared additional costs to maternal quality-adjusted life-years (QALYs). This expresses cost-effectiveness in terms of additional cost per additional QALY gained, which can be interpreted against common Australian benchmarks, whereby programmes with a cost-per-QALY of under $A50 000 are judged to be cost-effective.17

Participants and procedures

The right@home RCT was implemented from 2013 in two states of Australia, Victoria and Tasmania, in accordance with Consolidated Standards of Reporting Trials requirements.14 18 Detailed methods are published elsewhere.14 Briefly, researchers recruited 722 pregnant, English-speaking women, prioritised for their experience of adversity (at least two of: young pregnancy; not living with another adult; no support in pregnancy; poor health; a long-term illness, health problem or disability that limits daily activities; currently smokes; stress, anxiety or difficulty coping; low education; no person in the household currently earning an income; and never having had a job before) who attended antenatal clinics at 10 public maternity hospitals from 30 April 2013 to 29 August 2014.14 18 Participants enrolled by providing informed consent and completing a baseline interview. Participants randomised to the intervention (the right@home NHV programme, n=363) were offered a schedule of 25 home visits (60–90 min each) from pregnancy to child age 2 years instead of the usual 8 CFH visits. The NHV programme was delivered by a right@home-trained nurse recruited from the usual CFH service, and one or more visits from right@home-trained social care practitioners who provided psychosocial support for the families: brief counselling, assisting families with housing, service access and financial issues (one dedicated social care practitioner per site, per 100 families)3 Participants allocated to usual care (n=359) received the universal CFH service, which included 6 (Tasmania) or 9 (Victoria) mainly office-based consultations to child age 2 years. When the NHV intervention finished at 2 years, N=558 families enrolled in extended follow-up to 6 years.

Outcome measures

At the original endpoint of 2 years, the primary outcomes were multiple measures of parenting and the home environment; half showed small-to-moderate effect sizes (ES) in favour of the intervention and none favoured usual care.18 At 3 years, outcomes included multiple maternal health and well-being and child health and learning outcomes (see online supplemental table 1). For this paper, the Assessment of Quality of Life (AQoL-8D)19 was used to capture mothers’ health-related quality of life at four time-points (baseline and child ages 1, 2, 3 years); we used the health-related utility score to calculate QALYs.19 QALYs were calculated as linear interpolation using AQoL data at time points x and (x+1). Data were complete at baseline; where data were missing at later time points, QALYs were interpolated over a maximum of 2 years (from x to (x+2)). We did not estimate QALYs for children.

Economic evaluation

Costs are based on the health resources used by the woman and her child from recruitment to child age 3 years. Data on birth hospital admission and NHV/CFH service use (including the number and type, eg, home/clinic/phone) were extracted from service records. Other health resources including hospital admissions and community-based services were self-reported by women in interviews conducted by phone (at child ages 6 weeks, and 6, 18 and 30 months) and face-to-face (at baseline and child ages 1, 2 and 3 years). Participants were asked to recall service use since the last questionnaire for hospital admissions (inpatient, outpatient and emergency visits) and community-based services (eg, general practice and specialist physician visits, breastfeeding/lactation consultations, use of helplines, pharmacy, physiotherapy). Unit costs for each item of service use were sourced from national-level estimates where possible (table 1). All costs are presented in 2016/2017 Australian dollars. Implementation costs of NHV/CFH included nurse/practitioner visits, training, supervision and overheads. Nurses in both trial arms had similar qualifications (registered midwife/nurse with additional qualifications in maternal and child health).14 Unit costs of CFH nurse visits were confirmed with providers and included travel time and costs, standard materials and overheads ($A330 per home visit, $A110 per clinic visit). Costs for the additional online and face-to-face training received by right@home (intervention) nurses included trainer and nurse time, venue hire, catering, materials and travel. These training costs were distributed over an assumed 5-year caseload of 60 women to avoid artificially overloading training costs onto the restricted number of RCT participants. The right@home programme was associated with slightly higher supervision load than usual CFH service care, additional social worker time and parent materials costs.20 These ‘additional intervention costs’ are accrued per-nurse and allocated top-down to each participant.
Table 1

Unit cost of health resources

ServiceUnit cost 2016/2017, $AUnitResource
Hospital emergency department$A377.00Per admissionIndependent Hospital Pricing Authority20
Hospital outpatient clinic$A287.17Per eventIndependent Hospital Pricing Authority34
Hospital postnatal clinic$A226.39Per eventIndependent Hospital Pricing Authority34
Hospital breast feeding clinic$A226.39Per eventIndependent Hospital Pricing Authority34
Other hospital clinics$A287.17Per eventIndependent Hospital Pricing Authority34
Hospital same-day admission$A1249.00Per admissionIndependent Hospital Pricing Authority34
Hospital overnight admission$A2065.00Per dayIndependent Hospital Pricing Authority34
Lactation consultation$A45.40Per visitMedicare Benefits Schedule Item 8214035
Parenting centre day stays$A373.04Per admissionExpert’s opinion: Victorian parenting centres: private patients
Parenting centre night stays$A734.35Per nightExpert’s opinion: Victorian parenting centres: private patients
Hospital midwife visit$A226.39Per visitIndependent Hospital Pricing Authority34
CFHS clinic consultation$A110.00Per visitExpert’s opinion: From intervention team
CFHS home consultation$A330.00Per visitExpert’s opinion: From intervention team
CFHS phone consultation$A66.00Per visitAustralian Psychology Association36
Social care practitioner$A75.95Per visitMedicare Benefits Schedule Item 8016037
Helpline consultation$A20.72Per callFair work ombudsmen –Nurses Awards38
General Practice$A37.05Per visitMedicare Benefits Schedule Item 02339
Psychologist$A52.25Per visitMedicare Benefits Schedule Item 1096840
Psychiatrist$A221.30Per visitMedicare Benefits Schedule Item 29628
Paediatrician$A224.35Per visitMedicare Benefits Schedule Item 13541
Obstetrician/gynaecologist$A224.35Per visitMedicare Benefits Schedule Item 13242
Physiotherapy$A52.25Per visitMedicare Benefits Schedule Item 8133543
Osteo/chiro practitioner$A52.25Per visitMedicare Benefits Schedule Item 1096643
Dentist$A66.36Per visitAustralian fee schedule of dental services44
Drug and alcohol services$A176.08Per visitIndependent Hospital Pricing Authority34

CFHS, Child and Family Health Services.

Unit cost of health resources CFHS, Child and Family Health Services.

Patient and public involvement

There was no patient and public involvement in the development or analysis of the study

Analyses

Methods to address missing data: Characteristics of women who participated vs those lost to follow-up at 3 years were compared using t tests for continuous and χ2 tests for categorical data. For the total health service cost and its subcategories (hospital clinics, hospital admissions and primary health services), maternal and child outcomes, and QALY analyses, multiple imputation was used to account for lost to follow-up and missing data. Multiple imputation was conducted using multivariate normal regression within each of the two treatment groups to allow for differing mechanisms by which missing data may have arisen across the groups. Imputation models included all outcomes collected at 3 years, stratification factors and baseline covariates; 30 data sets were imputed. The health service use and intervention cost variables were not imputed because the high levels of missing data and collinearity prevented robust imputation; complete case data are presented for analyses involving these variables. All comparisons are reported as mean differences (MDs) and OR, with 95% CIs obtained using linear regression and logistic regression models, respectively, adjusted for baseline characteristics of, child sex, family’s Socio-Economic Index For Area (SEIFA) score, maternal education, maternal age at child’s birth, parity, antenatal risk, maternal self-efficacy and maternal mental health; plus child age at the 3-year assessment. Results in the tables are reported MDs, standardised ES or ORs with 95% CI. To make comparisons of intervention effect comparable between outcomes, standardised ES were obtained by running the linear regression described above on Z-scores calculated on each of the continuous outcomes. Between-group analyses of health service use were grouped into hospital outpatient clinics, hospital (inpatient) admissions and primary health services, presented as the cost of service use per year. As cost data relate to the use of resources over 3 years, costs after the first year are discounted at 5% (the rate required by Australian guidelines)21 to present costs in net present value terms.22 In economic evaluation, QALYs over 3 years are similarly discounted. All regression analyses accounted for effects of nurse clustering.14 18 The incremental cost-effectiveness ratio (ICER) was calculated as the MD in costs between intervention and usual care groups at 3 years divided by the MD in QALYs between groups at 3 years.23 This presents the extra cost for each additional QALY gained. Uncertainty was illustrated using a cost effectiveness plane showing 95% CIs around the ICER generated using the bootstrap method (1000 simulations) and a cost effectiveness acceptability curve, which visually represents the probability that the intervention (compared with usual care) is cost-effective at varying threshold values of one QALY ($A0–$A1.5m).17 Analyses were conducted in Microsoft Excel and Stata V.16.24

Results

Participant characteristics

At 3 years, 495 women (89% of N=558 re-enrolled, 69% of original N=722) (table 2 and figure 1) women provided data. More women were lost to follow-up who during pregnancy were younger, unemployed, reported high antenatal risk or poor mental health, or spoke a language other than English (table 2).
Table 2

Baseline characteristics according to follow-up status (ie, retained or lost) at child age 3 years

Baseline characteristics (pregnancy)Total (N=722)Intervention (N=363)Control (N=359)P value
Retained (N=495)Lost (N=227)P value*Retained (N=255)Lost (N=108)Retained (N=240)Lost (N=119)
Mother
 Age (years), mean (SD)28.0 (6.2)27.0 (6.3)0.0527.6 (5.9)27.1 (6.4)28.3 (6.4)26.9 (6.2)0.22
 DASS depression, mean (SD)2.9 (3.3)3.2 (3.8)0.413.0 (3.5)3.3 (4.0)2.8 (3.1)3.1 (3.6)0.42
 DASS anxiety, mean (SD)3.4 (3.3)3.9 (3.6)0.063.5 (3.4)3.9 (3.5)3.3 (3.1)3.8 (3.7)0.49
 DASS stress, mean (SD)5.4 (4.0)5.6 (4.5)0.435.3 (4.0)6.0 (4.8)5.4 (3.9)5.3 (4.3)0.77
 DASS depression, >85 th percentile score15.419.80.1417.318.513.321.00.23
 DASS anxiety, >85 th percentile score39.848.00.0440.849.138.847.10.64
 DASS Stress, >85 th percentile score19.619.40.9519.222.220.016.80.83
Education status0.560.43
 Did not complete high school23.827.721.333.726.522.3
 Completed high school/vocational training65.162.667.058.763.266.0
 Completed a university degree11.09.711.77.610.311.7
Marital status0.420.54
 Single/not living with partner26.129.129.026.922.931.1
 Married/living with partner72.368.369.470.475.466.4
 Separated/divorced1.62.61.62.81.73.5
 Currently unemployed62.873.60.00562.873.262.974.00.97
 Family income from benefit or pension41.844.90.4442.447.241.342.90.26
 Ever had a drug problem12.621.70.00212.218.513.024.60.78
 Experienced domestic violence in past year10.614.60.1310.715.910.613.50.97
 Quality of life: AQoL (SD)0.6 (0.2)0.6 (0.2)0.530.6 (0.2)0.6 (0.2)0.6 (0.2)0.6 (0.2)0.85
 Life satisfaction: Personal Well-being Index (SD)58.6 (10.6)58.7 (11.7)0.8759.2 (10.6)59.1 (11.0)58.4 (12.4)57.9 (10.5)0.17
Child
 First born36.837.40.8638.834.334.640.30.33
 Female51.744.30.07557.346.945.841.90.01
Family
 SEIFA Index of Social Disadvantage Quintile0.770.55
 1 (most disadvantaged)42.142.944.245.239.840.9
 27.79.16.89.68.78.7
 339.234.739.432.739.036.5
 48.19.66.411.510.07.8
 5 (least disadvantaged)2.93.73.21.02.66.1
 Language other than English7.211.70.0456.810.37.613.00.71

Range of total N=696–722, intervention N=351–363, control N=345–359 due to missing data.

All values are percentages, except where otherwise stated.

Percentages may not add up to 100 due to rounding

*P value for χ2 tests (categorical measures) and t-tests (continuous measures) comparing those lost to those retained for the combined cohort.

†P value for χ2 tests (categorical measures) and t-tests (continuous measures) comparing those retained in the intervention and usual care groups.

AQoL, Assessment of Quality of Life; DASS, depression, anxiety, stress scale; SEIFA, socioeconomic indexes for areas index of relative disadvantage.

Figure 1

Participant flow chart.

Baseline characteristics according to follow-up status (ie, retained or lost) at child age 3 years Range of total N=696–722, intervention N=351–363, control N=345–359 due to missing data. All values are percentages, except where otherwise stated. Percentages may not add up to 100 due to rounding *P value for χ2 tests (categorical measures) and t-tests (continuous measures) comparing those lost to those retained for the combined cohort. †P value for χ2 tests (categorical measures) and t-tests (continuous measures) comparing those retained in the intervention and usual care groups. AQoL, Assessment of Quality of Life; DASS, depression, anxiety, stress scale; SEIFA, socioeconomic indexes for areas index of relative disadvantage. Participant flow chart.

Health service use and cost

Compared with usual care, the NHV programme was associated with total increased costs over 3 years of $A7829 (95% CI $A4157 to $A11501) per family (table 3). This largely reflects the increased cost of nurse visits (primary health services category), due to increased number of visits received (see online supplemental table 2) and increased proportion of home visits. The mean cost of nurse visits to child age 3 years summed to $A6772 in the intervention group and $A966 in the control group. Combined with social care practitioner visits and additional intervention costs, service costs were $A9415 in right@home compared with $A2162 in usual care, that is, an additional cost of $A7254. As the intervention was delivered more intensively in the first year of child’s life, the extra costs are largely accrued in the first year.
Table 3

Health service use and intervention costs (complete case analysis for discounted costs)

All costs in $A 2016/2017Right@home n=363Usual care n=359Mean differenceP value95% CI
NCost (mean (SD))NCost (mean (SD))
Hospital clinics
 Year 13172039.22 (2359.38)3041763.29 (1625.18)275.930.046−45 to 596
 Year 22511026.20 (1639.31)2261164.85 (2278.54)−138.650.221−493 to 216
 Year 31981022.64 (2054.50)1911046.28 (1842.15)−23.640.453−413 to 365
Hospital admissions
 Year 13366003.54 (29573.97)3303375.36 (11250.94)2628.180.066−788 to 6044
 Year 23092680.74 (8428.60)2902157.86 (5498.19)522.870.186−627 to 1673
 Year 32632294.75 (7173.01)2472658.35 (7729.91)−363.600.291−1660 to 933
Primary health services (includes NHV intervention)
 Year 13036987.26 (2727.84)3172687.93 (1637.63)4299.330.0003946 to 4652
 Year 22923270.64 (1906.34)3061438.18 (1304.89)1832.450.0001571 to 2094
 Year 32471077.48 (1367.65)230936.34 (1014.95)141.140.102−77 to 359
Total health service cost
 Year 128113 144.14 (20 147.19)2807861.09 (12 864.79)5283.050.0002479 to 8088
 Year 22196564.58 (9339.43)2124922.15 (7592.48)1642.430.02328 to 3257
 Year 31893967.05 (6981.44)1794275.19 (7935.25)−308.150.346−1838 to 1223
Additional intervention costs*
 Year 1363826.29 (0.00)359347.52 (0.00)478.77
 Year 2363382.15 (0.00)359347.52 (0.00)34.63
Total cost
 Year 128113 970.43 (20 147.0)2808208.61 (12 864.79)5761.820.0002957 to 8566
 Year 22196928.53 (9339.43)2125253.12 (7592.48)1675.410.02161 to 3290
 Year 31893967.05 (6981.44)1794275.19 (7935.25)−308.150.346−1838 to 1222
 Over 3 years12122 766.04 (15 785.79)11914 937.22 (12 922.61)7828.820.0004157 to 11 501

*Training/material/supervision costs at the nurse level, in addition to the intervention costs included in primary health services.

†Unadjusted mean costs.

NHV, nurse home visiting.

Health service use and intervention costs (complete case analysis for discounted costs) *Training/material/supervision costs at the nurse level, in addition to the intervention costs included in primary health services. †Unadjusted mean costs. NHV, nurse home visiting. Other health service use varied, with no clear patterns across groups and no statistical evidence of differences at the aggregate level when combining all categories (except the above-mentioned primary health services) in any year or combining any category over 3 years. However, in the first year, the intervention group had higher use of hospital clinics and admissions than the usual care group. At the disaggregated level (online supplemental table 2), we can see that this is driven by a higher number of visits by both mothers and babies to hospital outpatient clinics, and higher emergency department visits in the child’s first year, which is reversed in the second year.

Health outcomes and cost–consequences analysis

Table 4 shows that, compared with the usual care group, women in the intervention group reported improved mental health (Total Depression, Anxiety, Stress Scale score ES=0.18, 95% CI 0.00 to 0.36) at child age 3 years. There was little evidence for group differences in child outcomes. The difficulty in comparing a substantial cost difference to a combination of ES across different outcome measures in cost-consequences analysis (table 4) is a reason to progress to the pre-specified secondary cost–utility analysis.
Table 4

Cost–consequences analysis of right@home at 3 years against all health-related outcomes (using multiple imputation)

OutcomeDescriptive statisticsComparative statistic: Intervention compared with control
Right@home (I)Usual care (C)AdjustedEffect size95% CI
MeanMeanMean difference95% CIP value
Parent care
 Warm parenting4.634.64−0.02−0.13 to 0.080.622−0.05−0.26 to 0.17
 Hostile parenting (reverse)7.947.760.18−0.16 to 0.520.2590.10−0.09 to 0.29
 Parenting efficacy8.077.910.16−0.15 to 0.480.2840.10−0.09 to 0.28
 Child–parent conflict (reverse)22.2521.240.98−0.34 to 2.300.1340.14−0.05 to 0.33
 Child–parent closeness32.2832.33−0.10−0.73 to 0.530.739−0.03−0.21 to 0.15
Maternal health
 Mental health: DASS—overall (Reverse scored)53.7951.741.850.05 to 3.650.0450.180.00 to 0.36
 Quality of life: AQoL0.720.680.04−0.01 to 0.080.0950.18−0.04 to 0.39
 Stress: maternal hair cortisol (pg/mg, reverse log transformed*)1.491.580.10−0.12 to 0.320.3590.10−0.12 to 0.31
 Life satisfaction: Personal Well-being Index58.9556.232.37−0.59 to 5.340.1030.17−0.04 to 0.37
Child language
 Receptive and expressive language: CELF sentence structure9.048.740.12−0.55 to 0.800.6990.04−0.17 to 0.25
 Receptive and expressive language: CELF word structure7.947.630.15−0.60 to 0.890.6820.04−0.18 to 0.26
 Receptive and expressive language: CELF expressive vocabulary8.318.000.19−0.46 to 0.840.5320.06−0.14 to 0.26
 Receptive and expressive language: CELF core language90.7589.010.83−2.60 to 4.270.6090.05−0.16 to 0.26
Child health
 Mental health and behaviour: SDQ externalising problems (reverse)11.6211.350.11−0.78 to 1.000.7920.02−0.17 to 0.22
 Mental health and behaviour: SDQ internalising problems (reverse)16.0315.850.14−0.38 to 0.660.5800.04−0.13 to 0.22
 Mental health and behaviour: SDQ total behaviour problems (reverse)27.6627.190.25−0.87 to 1.360.6390.04−0.14 to 0.22
 Quality of life: PedsQL physical well-being90.9989.421.51−1.17 to 4.180.2440.12−0.09 to 0.32
 Quality of life: PedsQL socioemotional well-being85.3383.531.67−1.20 to 4.540.2350.12−0.08 to 0.31
 Stress: child hair cortisol (pg/mg, reverse log transformed*)1.931.69−0.24−0.54 to 0.060.106−0.21−0.47 to 0.06
Economic
 Total costs $A  26 192  18 507  7685  7006; 83640.0000.280.26; 0.31

Adjusted for baseline characteristics of: child sex, family’s Socio-Economic Index for Areas score, maternal education, maternal age at child’s birth, parity, antenatal risk, maternal self-efficacy and maternal mental health; plus child age at the 3 years assessment.

*Natural log.

AQoL, assessment of quality of life; CELF, clinical evaluation of language fundamentals; CPRS, Child Parent Relationship Scale; DASS, Depression, Anxiety, Stress Scale; PedsQL, paediatric quality of life inventory; SDQ, Strengths and Difficulties Questionnaire.

Cost–consequences analysis of right@home at 3 years against all health-related outcomes (using multiple imputation) Adjusted for baseline characteristics of: child sex, family’s Socio-Economic Index for Areas score, maternal education, maternal age at child’s birth, parity, antenatal risk, maternal self-efficacy and maternal mental health; plus child age at the 3 years assessment. *Natural log. AQoL, assessment of quality of life; CELF, clinical evaluation of language fundamentals; CPRS, Child Parent Relationship Scale; DASS, Depression, Anxiety, Stress Scale; PedsQL, paediatric quality of life inventory; SDQ, Strengths and Difficulties Questionnaire. There was statistically significantly improved maternal QALYs in the third year (figure 2 and table 5) but no overall significant difference over the whole 3-year period (table 5).
Figure 2

QALYs over 3 years, using imputed data.

Table 5

Quality-adjusted life-years (QALYs) (using multiple imputation)

OutcomeDescriptive statistics QALYsComparative statistic: intervention compared with control
Right@home (I)Usual care (C)Adjusted*Effect size95% CI
MeanMeanMean difference95% CIP value
Year 10.68 (0.16)0.68 (0.16)0.00−0.00 to 0.000.880.00−0.02 to 0.03
Year 20.69 (0.17)0.69 (0.15)0.00−0.01 to 0.010.12−0.02−0.04 to 0.01
Year 30.65 (0.16)0.64 (0.16)0.01−0.00 to 0.010.000.050.03 to 0.08
Over 3 years2.02 (0.46)2.01 (0.43)0.01−0.01 to 0.020.360.01−0.01 to 0.04

*Adjusted for baseline characteristics of: quality of life, child sex, family’s Socio-Economic Index for Areas score, maternal education, maternal age at child’s birth, parity, antenatal risk, maternal self-efficacy and maternal mental health; plus child age at the 3-year assessment.

Quality-adjusted life-years (QALYs) (using multiple imputation) *Adjusted for baseline characteristics of: quality of life, child sex, family’s Socio-Economic Index for Areas score, maternal education, maternal age at child’s birth, parity, antenatal risk, maternal self-efficacy and maternal mental health; plus child age at the 3-year assessment. QALYs over 3 years, using imputed data.

Incremental cost effectiveness ratio

The ICER of the NHV intervention compared with usual care was estimated to be $A195 675 per QALY gained using complete case analysis and $A258 476 per QALY using multiply imputed data taking account of missing data and lost to follow-up. While all simulated cases demonstrated increased costs associated with the intervention, effects were far less certain (figure 3). The cost-effectiveness acceptability curve supports this, showing less than 20% probability of cost-effectiveness at a willingness-to-pay of $A50 000 per QALY at 3 years.
Figure 3

Cost-effectiveness plane and cost-effectiveness acceptability curve. QALYs, quality-adjusted life-years.

Cost-effectiveness plane and cost-effectiveness acceptability curve. QALYs, quality-adjusted life-years.

Discussion

The economic evaluation confirms that the provision of a higher intensity and home-based nursing service in the right@home NHV programme resulted in substantially increased healthcare costs. We found limited group differences in all other health resource use and associated costs up to child age 3 years. There was evidence of benefits to maternal mental health at child age 3 years, which combined with benefits to parenting at 2 years, translate into marginal maternal QALY gains. At 12 months post-intervention, the intervention is not cost-effective. The implementation costs of the right@home NHV programme ($A7254) are similar to the range of costs reported for NHV programmes in other high-income countries. The NFP estimated programme costs of US$1226512 ($A17 503 in 2016/2017 prices),25 26 the Building Blocks programme (based on NFP) in England estimated additional costs of GBP1812 ($A4166)4 and an earlier NHV programme in England estimated additional costs of GBP3246 ($A9523).27 Two previous studies have assessed the impact of NHV programmes on QALYs. A 2011 economic evaluation of the Denver NFP to child age 9 years estimated 0.15 additional QALYs accrued to mother/child dyad over the 9-year period, largely from reduced maternal depression.9 28 An economic evaluation of the UK’s family nurse partnership programme (Building Blocks) to child age 2 found 0.0036 additional QALYs per mother (95% CI −0.017 to 0.025).4 In comparison, we find 0.01 additional QALYs per mother (95% CI −0.01 to 0.02) to child age 3. Economic evaluations of NHV programmes assess whether the benefits generated by the programme represent value for money in comparison to the programme costs. In the US healthcare system, the NFP programme has generated increasing health and economic benefits over time. Cost savings to government are estimated to outweigh upfront programme costs between child age 9 and 30, depending on the effectiveness estimates used in analysis.9 12 29 This means that decision making on NHV programmes should consider costs and outcomes over a sufficiently long time period, despite the inherent conflict between policy/decision timing and availability of follow-up data. While the right@home NHV programme is not cost-effective at 12 months post-intervention, cost-effectiveness may improve over time if benefits continue to accrue to mothers and/or children; ongoing follow-up of right@home will collect cost and outcome data up to school age. Applications of NHV programmes in high-income countries have sought to address whether the positive results in the US context can be replicated when NHV is added to an existing universal healthcare system. In Australia, for example, ‘usual care’ represents a higher level of CFH service delivery compared with the US context. The concept that NHV offers a small change from existing service delivery is posited as an explanation for lack of positive outcomes for trials of NHV in England.4 For the right@home NHV programme at child age 3 years, the economic evaluation demonstrates increased costs and only limited benefits; however, these findings may change at older ages in line with previous studies and the general early intervention literature where benefits emerge as children age and enter adulthood with benefit lags up to 30 years post-intervention.12 Broader health service use costs were slightly higher for right@home compared with usual care in the first year, with some reversal in later years. The increased professional contact of the NHV programme may directly identify health concerns, or improve predisposing individual factors like knowledge and awareness to prompt women to use healthcare services more often.30 This should be interpreted as a positive outcome, as increasing women’s connection to and use of appropriate services is an objective of this and other NHV programmes. Although any increased use of services will have additional costs to government providers, if this is filling or narrowing a gap in appropriate care, it may well lead to concomitant or future improvements in health outcomes. Strengths of the trial include the rigorous design and outcome assessments completed by researchers who were blinded to intervention status. The research retained a high proportion of study participants in both groups (69% over a 4-year study duration), despite the substantial adversity experienced by participants. For context, by the 2-year follow-up, the Building Blocks study retained 71% of their cohort for self-reported outcomes31 and other European studies retained less than 50%.6 32 Given the large, multisite design of the trial, high participant retention and use of multiple imputation to address missing data arising from participant attrition, we believe our findings should generalise to pregnant women experiencing adversity, in similar healthcare systems. There are several limitations. Maternal report was used to measure broader health service use and quality of life outcomes and responses may be subject to perception influenced by participation in the intervention. There is a possibility of recall bias when answering service use questions over a 6-month recall period, although any bias should be distributed equally across trial arms.33 Quality of life data for children were not included in QALY measures. Service use data excludes the use and costs of other government services such as child protection and associated legal services, as these data were not collected in this period of the trial. Women were more likely to be lost to follow-up if they were younger, unemployed or reported higher antenatal risk; despite multiple imputation of outcome data, the cost and cost-effectiveness results may not fully represent these women. In addition, trial exclusion criteria meant that findings may not generalise to non-English speaking women or women with severe intellectual disability.

Conclusion

The embedding of an NHV programme into the Australian universal health system demonstrates benefits to parenting and the home environment when the intervention ends at child age 2 years,18 and improves maternal mental health 12 months later. As expected, implementing an NHV programme requires substantial up-front investment. Economic evaluation based on the outcomes evident by child age 3 years shows a lack of cost-effectiveness, due to a lack of short term cost-savings and only marginal maternal QALY gain. Ongoing follow-up will assess whether continued accrual of benefits to mothers and children outweigh the increased up-front costs as shown in other NHV programs over a longer period of time.
  22 in total

1.  Revisiting the behavioral model and access to medical care: does it matter?

Authors:  R M Andersen
Journal:  J Health Soc Behav       Date:  1995-03

2.  The Australian Nurse-Family Partnership Program for aboriginal mothers and babies: Describing client complexity and implications for program delivery.

Authors:  Dorota Zarnowiecki; Ha Nguyen; John Boffa; Leonie Segal
Journal:  Midwifery       Date:  2018-06-23       Impact factor: 2.372

3.  The nurse-family partnership: An evidence-based preventive intervention.

Authors:  David L Olds
Journal:  Infant Ment Health J       Date:  2006-01

4.  Economic evaluation of an intensive home visiting programme for vulnerable families: a cost-effectiveness analysis of a public health intervention.

Authors:  Emma McIntosh; Jane Barlow; Hilton Davis; Sarah Stewart-Brown
Journal:  J Public Health (Oxf)       Date:  2009-06-04       Impact factor: 2.341

5.  Adapting, piloting and evaluating complex public health interventions: lessons learned from the Nurse-Family Partnership in Canadian public health settings.

Authors:  S M Jack; N Catherine; A Gonzalez; H L MacMillan; D Sheehan; D Waddell
Journal:  Health Promot Chronic Dis Prev Can       Date:  2015 Oct-Nov       Impact factor: 3.240

6.  Accuracy of patient recall for self-reported doctor visits: Is shorter recall better?

Authors:  Kim Dalziel; Jinhu Li; Anthony Scott; Philip Clarke
Journal:  Health Econ       Date:  2018-07-02       Impact factor: 3.046

7.  Cost-effectiveness of the Family Nurse Partnership (FNP) programme in England: Evidence from the building blocks trial.

Authors:  Belen Corbacho; Kerry Bell; Eugena Stamuli; Gerry Richardson; Sarah Ronaldson; Kerenza Hood; Julia Sanders; Michael Robling; David Torgerson
Journal:  J Eval Clin Pract       Date:  2017-08-11       Impact factor: 2.431

8.  'right@home': a randomised controlled trial of sustained nurse home visiting from pregnancy to child age 2 years, versus usual care, to improve parent care, parent responsivity and the home learning environment at 2 years.

Authors:  Sharon Goldfeld; Anna Price; Hannah Bryson; Tracey Bruce; Fiona Mensah; Francesca Orsini; Lisa Gold; Harriet Hiscock; Charlene Smith; Lara Bishop; Dianne Jackson; Lynn Kemp
Journal:  BMJ Open       Date:  2017-03-20       Impact factor: 2.692

Review 9.  Systematic review of the economic evidence on home visitation programmes for vulnerable pregnant women.

Authors:  Eugena Stamuli; Gerry Richardson; Steven Duffy; Michael Robling; Kerry Hood
Journal:  Br Med Bull       Date:  2015-07-28       Impact factor: 4.291

10.  Predictors of Study Attrition in a Randomized Controlled Trial Evaluating a Perinatal Home-Visiting Program with Mothers with Psychosocial Vulnerabilities.

Authors:  Stéphanie Foulon; Tim Greacen; Blandine Pasquet; Romain Dugravier; Thomas Saïas; Nicole Guedeney; Antoine Guedeney; Florence Tubach
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.